Polymyalgia rheumatica/arteritis temporalis and acquired factor VIII inhibitor

被引：4

作者：

Gallant M. ^{[1
]}

Lories R. ^{[2
]}

Verbanck J. ^{[3
]}

机构：

[1] Department of Internal Medicine, University Hospitals Leuven, Leuven

[2] Department of Rheumatology, University Hospitals Leuven, Leuven

[3] Department of Nephrology, Heilig Hart Ziekenhuis Roeselare, Roeselare

来源：

Clinical Rheumatology | 2008年 / 27卷 / Suppl 1期

关键词：

Acquired haemophilia; Arteritis temporalis; Factor VIII inhibitor; Polymyalgia rheumatica;

D O I：

10.1007/s10067-007-0817-5

中图分类号：

学科分类号：

摘要：

Acquired haemophilia is a rare, but often life-threatening bleeding disorder caused by autoantibodies, mostly directed against factor VIII (FVIII inhibitor). The incidence of acquired haemophilia, which most commonly affects patients over 50 years of age, is estimated between 0.2 and 1 million per year. Although its aetiology remains obscure, 40-50% of cases are associated with other conditions, such as pregnancy, malignancies, drugs and autoimmune disorders as rheumatoid arthritis, systemic lupus erythematosus and Sjögren's disease. We report the case of a 69-year-old patient with spontaneously acquired FVIII inhibitor secondary to polymyalgia rheumatica (PMR)/arteritis temporalis (AT). Our case illustrates that PMR/AT can be added to the list of autoimmune disorders associated with acquired haemophilia due to FVIII inhibitor. © Clinical Rheumatology 2007.

引用

页码：19 / 21

页数：2

共 6 条

[1] Holme P.A., Brosstad F., Tjonnfjord G.E., Acquired haemophilia: Management of bleeds and immune therapy to eradicate autoantibodies, Haemophilia, 11, pp. 510-515, (2005)
[2] Huang Y.-W., Saidi P., Philipp C., Acquired factor VIII inhibitors in non-haemophilic patients: Clinical experience of 15 cases, Haemophilia, 10, pp. 713-721, (2004)
[3] Delgado J., Jimenez-Yuste V., Hernandez-Navarro F., Villar A., Acquired haemophilia: Review and meta-analysis focused on therapy and prognostic factors, Br J Haematol, 121, pp. 21-35, (2003)
[4] Green D., Lechner K., A survey of 215 non-hemophilic patients with inhibitors to factor VIII, Thromb Haemost, 45, pp. 200-203, (1981)
[5] Hay C., Brown S., Collins P.W., Keeling D.M., Liesner R., The diagnosis and management of factor VIII and IX inhibitors: A guideline from the United Kingdom Haemophilia Centre Doctors Organisation, Br J Haematol, 133, pp. 591-605, (2006)
[6] Ma A.D., Carrizosa D., Acquired factor VIII inhibitors: Pathophysiology and treatment, Hematology (Am Soc Hematol Educ Program), pp. 432-437, (2006)

← 1 →